HHS Secretary Kathleen Sebelius announced Tuesday during a House Energy and Commerce Committee hearing that H1N1 (swine flu)
vaccines produced by four manufacturers — CSL Ltd., Novartis, Sanofi-Pasteur and Medimmune — had won FDA approval, paving the way for a U.S. large-scale vaccination campaign,
The Wall Street Journal reports. The application for GlaxoSmithKline PLC's
vaccine is still being considered (Dooren/Favole, 9/15).
According to CQ HealthBeat, HHS anticipates having some supplies of H1N1
vaccine available as early as October 5 (Attias, 9/15), but "[t]he bulk of
vaccine will start arriving Oct. 15, and Sebelius said it should be available at 90,000 sites around the country,"
The Associated Press/TIME reports. "'We will have enough
vaccine available for everyone' eventually, Sebelius said — everyone who wants it, that is." The U.S. government currently has contracts to buy 195 million doses of the H1N1
vaccine, but will buy more if demand is high, Sebelius explained (Neergaard, 9/15).
The large-scale vaccination campaign, scheduled to begin in mid-October, will first target those at greatest risk from H1N1, including health care workers, pregnant women and young people ages 6 months to 24 years.
Reuters writes: "H1N1
vaccines will be free, Sebelius said, but some healthcare providers may charge an administration fee. The federal government is planning to spend about $1.4 billion for states and hospitals to prepare for the
virus, she added" (Heavey, 9/15).
This is part of Kaiser Health News' Daily Reports - a summary of health policy coverage from more than 300 news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Reports here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.
Subscribe